Mesh : Alzheimer Disease / drug therapy genetics metabolism pathology Animals Autistic Disorder / drug therapy genetics metabolism pathology Autophagy / drug effects Cytoskeleton / drug effects genetics metabolism pathology Drug Discovery Gene Expression Regulation / drug effects Homeodomain Proteins / genetics metabolism Humans Nerve Tissue Proteins / genetics metabolism Neuroprotection / drug effects Oligopeptides / pharmacology therapeutic use Protein Interaction Maps / drug effects Schizophrenia / drug therapy genetics metabolism pathology

来  源:   DOI:10.1515/hsz-2015-0152   PDF(Sci-hub)

Abstract:
Fifteen years ago we discovered activity-dependent neuroprotective protein (ADNP), and showed that it is essential for brain formation/function. Our protein interaction studies identified ADNP as a member of the chromatin remodeling complex, SWI/SNF also associated with alternative splicing of tau and prediction of tauopathy. Recently, we have identified cytoplasmic ADNP interactions with the autophagy regulating microtubule-associated protein 1 light chain 3 (LC3) and with microtubule end-binding (EB) proteins. The ADNP-EB-binding SIP domain is shared with the ADNP snippet drug candidate, NAPVSIPQ termed NAP (davunetide). Thus, we identified a precise target for ADNP/NAP (davunetide) neuroprotection toward improved drug development.
摘要:
暂无翻译
公众号